sparX-HER2

sparX-HER2 is a preclinical-stage soluble adapter protein developed by Arcellx (and subsequently acquired by Gilead Sciences) as part of its proprietary ARC-SparX platform. The ARC-SparX system is designed to provide controllable and adaptable CAR-T cell therapy by decoupling the tumor-targeting and T-cell activation functions. sparX-HER2 is a bivalent, affinity-tuned fusion protein consisting of a synthetic D-domain that specifically binds to human epidermal growth factor receptor 2 (HER2) on tumor cells, fused to a tag derived from human alpha-fetoprotein (AFP). When administered alongside universal antigen-receptor complex T (ARC-T) cells, sparX-HER2 acts as a bridge, linking the ARC-T cells to HER2-overexpressing tumor cells and triggering dose-dependent T-cell activation and tumor cell lysis. This modular design allows for precise control over T-cell activity through SparX dosing, potentially mitigating on-target off-tumor toxicities and cytokine release syndrome associated with conventional HER2-targeted CAR-T therapies.

Other names

HER2 sparXHER-2 sparXHER 2 sparXHER2-SparXHER-2-SparXHER 2-SparX